SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Ohlin Elisabet)
 

Search: WFRF:(Ohlin Elisabet) > The "motor complica...

The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration.

Lindgren, Hanna (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
Rylander, Daniella (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
Ohlin, Elisabet (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
show more...
Lundblad, Martin (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
Cenci Nilsson, Angela (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
show less...
 (creator_code:org_t)
Elsevier BV, 2007
2007
English.
In: Behavioural Brain Research. - : Elsevier BV. - 0166-4328. ; 177:1, s. 150-159
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • l-DOPA-induced motor complications can be modelled in rats with 6-hydroxydopamine (6-OHDA) lesions by chronic injections of l-DOPA. We have compared the sensitisation and duration of rotational responses, and the occurrence of dose–failure episodes and abnormal involuntary movements (AIMs) in 6-OHDA-lesioned rats with regard to the dose and route of administration of l-DOPA. Rats were treated with either low (6 mg/kg) or high (25 mg/kg) doses of l-DOPA twice daily for 21 days whereas control animals received injections of either saline or bromocriptine (2.5 mg/kg). A dose-dependent and gradual development of AIMs and contralateral turning was observed in rats treated chronically with l-DOPA. Rats treated with bromocriptine exhibited rotational sensitisation but no AIMs. A shortening of motor response duration was not seen in any of the drug-treated groups. In contrast, dose–failure episodes occurred frequently in both l-DOPA- and bromocriptine-treated animals. Changing the route of l-DOPA administration from intraperitoneal to subcutaneous completely abolished failures in motor response without affecting the development of dyskinesia. Based on the hypothesis that higher doses of l-DOPA may be toxic to dopaminoceptive structures, we compared the total number of neurons and the levels of activated microglia in the striatum. No signs of neurodegenerative changes could be seen in any of the treatment groups. In conclusion, both body AIMs and rotations were dose-dependently evoked by l-DOPA. Only AIMs, however, provided a specific measure of dyskinesia since rotations also were induced by bromocriptine, a drug with low dyskinesiogenic potential. Dose–failure episodes were not specific to l-DOPA treatment and could be attributed to erratic drug absorption from the peritoneal route.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

Striatum
Toxicity
Motor complications
Parkinson's disease
l-DOPA
6-OHDA

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Find more in SwePub

By the author/editor
Lindgren, Hanna
Rylander, Daniel ...
Ohlin, Elisabet
Lundblad, Martin
Cenci Nilsson, A ...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Neurosciences
Articles in the publication
Behavioural Brai ...
By the university
Lund University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view